FDA Intervention Status in 2026 — A Factual Timeline
As of March 2026, 19 interventions remain classified as FDA Category 2, restricting compounding pharmacy production. Despite widely reported announcements about reclassification, no formal FDA rule change has been published and no Federal Register updates have occurred. Compounding pharmacy restrictions remain legally in place.
What happened in September 2023?
The FDA moved 19 interventions to Category 2 under 503A/503B compounding regulations. This meant compounding pharmacies could no longer legally produce these compounds. The affected interventions included BPC-157, TB-500 (Thymosin Beta-4), AOD-9604, and others commonly used in the biohacking and intervention therapy communities.
What happened in February 2026?
On February 27, 2026, RFK Jr. appeared on the Joe Rogan Experience and announced plans to reclassify 14 of the 19 Category 2 interventions back to Category 1. This generated significant media coverage and public interest:
- Intervention-related search volume increased 37%
- 3.9 million monthly searches for intervention-related terms (SEMRush)
- Mainstream media coverage from NPR, CNN, and TIME
What has NOT happened?
As of March 2026:
- No formal FDA rule change has been published
- No Federal Register update has occurred
- No official reclassification order has been issued
- Compounding pharmacy restrictions remain legally in effect
- A public statement is not the same as a regulatory action
What is happening behind the scenes?
- Multiple industry groups have submitted formal reclassification petitions to the FDA
- Congressional inquiries have been made regarding the Category 2 classification
- Several state-level proposals addressing intervention access are in various legislative stages
- The compounding pharmacy industry is actively lobbying for reclassification
These are publicly documented developments, not speculation.
What does this mean for consumers?
The regulatory gap between public announcements and formal policy changes creates uncertainty:
- Some compounding pharmacies are producing interventions again; others are waiting for formal guidance
- Quality standards vary across compounding pharmacies
- Consumers accessing compounds during regulatory limbo face additional uncertainty
- The legal status of purchasing and using these compounds varies by jurisdiction
How does Narrated track regulatory status?
Narrated displays the current regulatory status of every compound — updated when official changes happen, not when announcements are made. We distinguish between:
- FDA-approved: Approved for specific indications (e.g., semaglutide as Ozempic/Wegovy)
- Category 1: Can be compounded by pharmacies under 503A/503B
- Category 2: Cannot be compounded — current status for 19 interventions
- Dietary supplement: Legal, over-the-counter (e.g., ashwagandha, creatine)
- Research chemical: Not approved for human use, available for research